Your browser doesn't support javascript.
loading
Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
Singini, Mwiza Gideon; Muchengeti, Mazvita; Sitas, Freddy; Chen, Wenlong Carl; Combes, Jean-Damien; Waterboer, Tim; Clifford, Gary M.
Afiliação
  • Singini MG; International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.
  • Muchengeti M; National Cancer Registry, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg, South Africa.
  • Sitas F; National Cancer Registry, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg, South Africa.
  • Chen WC; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
  • Combes JD; South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.
  • Waterboer T; Center for Primary Health Care and Equity, School of Population Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
  • Clifford GM; Menzies Center of Health Policy, School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Int J Cancer ; 155(2): 251-260, 2024 Jul 15.
Article em En | MEDLINE | ID: mdl-38577820
ABSTRACT
Human papillomavirus (HPV) proteins may elicit antibody responses in the process toward HPV-related malignancy. However, HPV seroepidemiology in noncervical HPV-related cancers remains poorly understood, particularly in populations with a high prevalence of human immunodeficiency virus (HIV). Using a glutathione S-transferase-based multiplex serology assay, antibodies against E6, E7 and L1 proteins of HPV16 and HPV18 were measured in sera of 535 cases of noncervical HPV-related cancers (anal (n = 104), vulval (n = 211), vaginal (n = 49), penile (n = 37) and oropharyngeal (n = 134)) and 6651 non-infection-related cancer controls, from the Johannesburg Cancer Study that recruited Black South African with newly diagnosed cancer between 1995 and 2016. Logistic and Poisson regression models were used to calculate adjusted odds ratios (aOR) and prevalence ratios (aPR) and 95% confidence intervals (CI) in cases versus controls. HPV16 E6 was more strongly associated with noncervical HPV-related cancers than HPV16 L1 or E7, or HPV18 proteins anal (females (HPV16 E6 aOR = 11.50;95%CI6.0-22.2), males (aOR = 10.12;95%CI4.9-20.8), vulval (aOR = 11.69;95%CI7.9-17.2), vaginal (aOR = 10.26;95%CI5.0-21), penile (aOR = 18.95;95%CI8.9-40), and oropharyngeal (females (aOR = 8.95;95%CI2.9-27.5), males (aOR = 3.49;95%CI1.8-7.0)) cancers. HPV16-E6 seropositivity ranged from 24.0% to 35.1% in anal, vulval, vaginal and penile cancer but was significantly lower (11.2%) in oropharyngeal cancer. After adjustment for HIV, prevalence of which increased from 22.2% in 1995-2005 to 54.1% in 2010-2016, HPV16 E6 seropositivity increased by period of diagnosis (aPR for 2010-2016 vs. 1995-2006 = 1.84;95%CI1.1-3.0). Assuming HPV16 E6 seroprevalence reflects HPV attributable fraction, the proportion of certain noncervical-HPV-related cancers caused by HPV is increasing over time in South Africa. This is expected to be driven by the increasing influence of HIV.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Proteínas Oncogênicas Virais / Infecções por Papillomavirus / Anticorpos Antivirais País/Região como assunto: Africa Idioma: En Revista: Int J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Proteínas Oncogênicas Virais / Infecções por Papillomavirus / Anticorpos Antivirais País/Região como assunto: Africa Idioma: En Revista: Int J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: França